Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy Participants

NCT06326606 is registered in ClinicalTrials.gov with MycoMedica Life Sciences PBC as lead sponsor.

NCT NCT06326606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06326606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy Participants
Lead sponsor
MycoMedica Life Sciences PBC
Phase
Phase 1
Overall status
Completed
Start date
March 27, 2024
Completion date
July 8, 2024
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers